期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 115, 期 11, 页码 3228-3238出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI22756
关键词
-
Vascular SMC proliferation is a crucial event in occlusive cardiovascular diseases. PPAR alpha is a nuclear receptor controlling lipid metabolism and inflammation, but its role in the regulation of SMC growth remains to be established. Here, we show that PPARa. controls SMC cell-cycle progression at the G(1)/S transition by targeting the cyclin-dependent kinase inhibitor and tumor suppressor p16(INK4a) (p16), resulting in an inhibition of retinoblastoma protein phosphorylation. PPARa activates p16 gene transcription by both binding to a canonical PPAR-response element and interacting with the transcription factor Sp1 at specific proximal Sp1-binding sites of the p16 promoter. In a carotid arterial-injury mouse model, p16 deficiency results in an enhanced SMC proliferation underlying intimal hyperplasia.. Moreover, PPAR alpha activation inhibits SMC growth in vivo, and this effect requires p 16 expression. These results identify an unexpected role for p16 in SMC cell-cycle control and demonstrate that PPARa. inhibits SMC proliferation through p16. Thus, the PPAR alpha/p16 pathway may be a potential pharmacological target for the prevention of cardiovascular occlusive complications of atherosclerosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据